Bayer's FDA First-Line Nod for Hyrnuo Adds Oncology Depth to a Year of 32% Gains
Published on 09/10/2026 at 12:31 | Editorial boerse-global.de
Bayer has secured accelerated approval from the U.S. Food and Drug Administration for Hyrnuo (sevabertinib), clearing the drug for first-line use in adults with locally advanced or metastatic, non-squamous, HER2-mutated non-small cell lung cancer (NSCLC). The decision, announced Thursday, broadens a label that until now covered only previously treated patients — the FDA had granted sevabertinib its initial go-ahead in November 2025. With the expansion, therapy-naive patients, typically the largest group in any indication, can now receive the drug.
The application moved through the agency's priority review track and carried a breakthrough therapy designation, markers of the FDA's view that the treatment addresses a serious unmet need.
What the SOHO-01 Data Show
Regulators leaned on the Phase I/II SOHO-01 trial (NCT05099172) to support the filing. Among 69 treatment-naive participants, sevabertinib produced an objective response rate of 75% — 6% complete responses and 70% partial responses. Responses proved durable: 73% of responders held their response for at least six months, and 38% for a year or longer. Patients take 20 milligrams orally twice daily with food.
Continued approval is contingent on the confirmatory Phase III SOHO-02 study (NCT06452277), a standard condition attached to accelerated authorizations. Diarrhea, rash, stomatitis, paronychia, nausea and weight loss were the most common side effects, each appearing in more than 20% of treated patients.
Should investors sell immediately? Or is it worth buying Bayer?
HER2 mutations account for roughly 2% to 4% of all NSCLC cases — a narrow but well-defined population. Sevabertinib, a reversible tyrosine kinase inhibitor, emerged from Bayer's alliance with the Broad Institute along with MIT and Harvard. It already holds approvals in China from the NMPA and in Japan from the MHLW.
A Crowded Field Awaits
Bayer will not have this niche to itself. Boehringer Ingelheim's rival agent Hernexeos posted a 77% objective response rate in first-line treatment — close to sevabertinib's figure, though the two drugs were tested in different populations and trial designs. Competition for HER2-mutated lung cancer patients looks set to stay fierce.
Beyond Oncology: Kerendia Widens Its Footprint
The oncology win is not the only recent bright spot. Study data showed Kerendia helps in hypertensive nephropathy, a kidney condition driven by high blood pressure, extending the reach of a medicine already cleared for chronic kidney disease linked to type 2 diabetes. Taken together with the string of regulatory and clinical milestones, the results underscore that Bayer's pharmaceutical division is advancing on several fronts at once — a meaningful signal for investors betting on a broader earnings base beyond the company's legal legacy issues.
Why the Stock Barely Moved
The market's muted reaction to the FDA news is hardly surprising. The shares closed Wednesday at EUR 49.06, down 0.6% on the prior session, and were trading at EUR 49.02 — essentially flat against that close and just above the 50-day average of EUR 48.68. The gap to the 52-week high of EUR 53.86 stands at about 9%, while an RSI of 53.6 points to neutral conditions, with neither overbought nor oversold readings in play.
Investors had already priced in much of the pipeline progress after a run of earlier sevabertinib approvals. The stock's real advance this year — a 32% gain since January — draws on a wider mix of themes: legal relief in the glyphosate litigation, a steadier balance sheet, and momentum in the agricultural business. Over a twelve-month horizon, the shares are up 75%, evidence that shareholders have been rewarding Bayer's fundamental repositioning for some time, with individual regulatory milestones treated more as confirmation than surprise.
The Road Ahead
Bayer is expected to report third-quarter 2026 results on November 3. Until then, the stock looks likely to trade between the tailwind of positive pharma headlines and the persistent legal uncertainty surrounding the glyphosate weedkiller. Volatility over the past 30 trading sessions sits at 19% — moderate by historical standards, but far from trivial. For investors, the pharmaceutical unit is increasingly carving out a role as an independent value driver alongside the familiar agricultural and litigation storylines.
Ad
Bayer Stock: New Analysis - 10 September
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
